《全日總結》恆指跌215點 生物科技股受挫 藥明生物瀉19%
8間中國科技企業傳將被美列禁止投資名單,以及多間中國生物科技公司或被美製裁,港股午後轉弱。恆指高開22點,早段曾升109點見23,745點,午後市況轉差,尾市曾跌310點見23,325點,全日跌215點或0.91%,收23,420點;國指跌75點或0.9%,收8,342點;恆生科技指數跌89點或1.52%,收5,795點。大市全日成交總額1,277.42億元,滬、深港通南下交易分別淨流入22.23億及22.53億元人民幣。
生物醫藥股重挫,藥明生物(02269.HK)及藥明康德(02359.HK)各跌19.2%及19.1%,信達生物(01801.HK)及中生製藥(01177.HK)各跌9.9%及5%。榮昌生物(09995.HK)跌17.3%,諾誠健華(09969.HK)、金斯瑞(01548.HK)及藥明巨諾(02126.HK)各跌逾11%。據報康希諾(06185.HK)正開展針對Omicron新冠疫苗研發工作,股價曾升15.7%,收市升幅收窄至2.5%。
科技股方面,阿裏巴巴(09988.HK)升1.9%報121元,騰訊(00700.HK)跌0.9%報455.8元,美團(03690.HK)及京東(09618.HK)各跌1.8%及1.6%,小米(01810.HK)及百度(09888.HK)各跌2.4%及2.7%。嗶哩嗶哩(09626.HK)跌4.6%,雲音樂(09899.HK)及萬國數據(09698.HK)各跌6.5%及8.3%。據報美國考慮對中芯(00981.HK)施加更嚴厲制裁,中芯跌6.4%報18.72元。同業華虹半導體(01347.HK)跌4.3%。
內房股方面,世茂股份(600823.SH)稱未發生影響公司償債能力和債券還本付息不利事項,世茂(00813.HK)高開後倒跌2.5%。富力(02777.HK)提出部分票據延期或以低於票面值贖回,富力跌3%。融創(01918.HK)及旭輝(00884.HK)各跌4.2%及4.5%。物管股碧桂園服務(06098.HK)半年內不配新股,主席承諾不減持,股價反彈1.9%。恆大海口8幅閒置地因逾期動工被政府無償收回,恆大(03333.HK)跌3.1%,同系恆大物業(06666.HK)跌3.5%。
金融股方面,匯控(00005.HK)升1%報44.95元,港交所(00388.HK)跌1.5%報455.8元,友邦(01299.HK)跌0.5%報79.55元。財險(02328.HK)跌3.5%,早前公佈首11個月原保險保費收入按年升1.6%。
多隻內需股走軟,維達(03331.HK)及中國飛鶴(06186.HK)各跌3.5%及4.8%,安踏(02020.HK)及李寧(02331.HK)各跌4.8%及3.1%,比亞迪(01211.HK)擬明年上半年發佈首款高端車,股價跌2.3%報271元。北汽(01958.HK)股價逆升15.3%。港澳通關憧憬支持濠賭股,新濠國際(00200.HK)及美高梅中國(02282.HK)各升4%及2.3%。
電力股受支持,華潤電力(00836.HK)及華能國電(00902.HK)各升4.8%及5.4%,大唐發電(00991.HK)及華電國際(01071.HK)各升7%及8.9%。光伏股保利協鑫(03800.HK)折讓2.4%配股籌51億元,該股升13.3%報2.89元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.